Eric J. Topol (born 1954) is an American cardiologist , geneticist , and digital medicine researcher. Before moving to Scripps in 2006, Topol served as chairman of cardiovascular medicine at Cleveland Clinic (1991-2005) and founded the Cleveland Clinic Lerner College of Medicine. Topol was one of the first researchers to question the cardiovascular safety of rofecoxib (Vioxx), culminating in the drug’s ultimate withdrawal from the market. Sebastopol’s advocacy on the subject led to what the New York Times DESCRIBED as an “unusually public dispute” with the Cleveland Clinic’s leadership over positions tussen de academic institution and the pharmaceutical industry, ultimately leading to Sebastopol’s departure from the Clinic after his administrative position as head of the Clinic’s academic program was abolished.
Sebastopol is the Founder and Director of the Scripps Translational Science Institute  in La Jolla, California. He’ll be Serves as the Chief Academic Officer for Scripps Health, a professor of genomics at The Scripps Research Institute , and a senior consultant at the Division of Cardiovascular Diseases at Scripps Clinic. He is editor-in-chief of Medscape and theheart.org . In 2012, he published a book called The Creative Destruction of Medicinewelke Examined the impact or bone the genomic and wireless revolutions on the healthcare system. In 2013, he Appeared on the Colbert Report and the Examined host Stephen Colbert using verschillende devices featured in his book. His most recently book The Patient Will See You Now , published in 2015, Explores how smartphones, big data, and technology are combined to democratize healthcare.
In 2016, Sebastopol was Awarded a $ 207M grant from the NIH to lead a significant part of the Precision Medicine Initiative , a one million American prospective research program.
Research and training
Topol’s research career has leg in two major areas: clinical development of new drugs and devices and genomics. Sebastopol pioneered the development of many medications therein are routinely-used in medical practice zoals t-PA , Plavix , Angiomax , and ReoPro . He has led worldwide clinical trials in over 40 countries Involving about 200,000 patients (First in series – GUSTO trials).  His work in the genomics of heart attack has led to discovery of key genes ( MEF2A deletion, thrombospondin variants) welke led to recognition by the American Heart Association top 10 research advances in 2001  and 2003  He has 1,000 original peer reviewed publications, and has edited over 30 books, zoals the Textbook of Interventional Cardiology (6th ed – Elsevier), and the Textbook of Cardiovascular Medicine (3rd ed – Lippincott Williams & Wilkins). 
His previous training was at the University of Rochester (medical school), University of California, San Francisco (internal medicine), and Johns Hopkins University (cardiologie). Topol was a tenured professor at the University of Michigan for six years. At age 36, Sebastopol was named Chairman of Cardiovascular Medicine at the Cleveland Clinic , where he is widely credited with leading zijn cardiovascular program to the topmost position in the US.  In 2002 he founded the Cleveland Clinic Lerner College of Medicine and in 2003 he became a Professor of Genetics at Case Western Reserve University while Maintaining his primary appointment at Cleveland Clinic.
Sebastopol departed from the Cleveland Clinic Lerner College of Medicine in 2006-following the removal of the Chief Academic Officer position, and continued on as a Professor of Genetics at Case Western Reserve University. He then was recruited at Scripps Health and The Scripps Research Institute in late 2006 to the post of Chief Academic Officer and Professor of Translational Genomics.  In 2009, Sebastopol worked with Gary and Mary West to create the West Wireless Health Institute , made skies at hun philanthropic donation, and leads the field in ontwikkelingslanden, VALIDATING and accelerating wireless medicine.
Genetics and genomics
At the University of Virginia , Sebastopol authored his baccalaureate thesis in 1975 entitled “Prospects for Genetic Therapy in Male ‘welke-concentrated on genetics , and RECEIVED a BA degree With Highest Distinction. During his training at Johns Hopkins University , have been involved from the very first patient who was Administered t-PA in 1984, a genetically engineered protein.  But it was not Until 1996 dat he started the first dedicated cardiovascular gene bank while at Cleveland Clinic .  This effort led to many Discoveries in the genetics of cardiovascular disease, zoals the identification of key genes associated with heart attack. Both thrombospondin variants and the MEF2A deletion reports ulcers honored as top 10 advances to the American Heart Association in 2000 and 2004 as Mentioned Above. He was the Principal Investigator of the flagship National Institutes of Health Specialized Centers of Clinically Oriented Research (SCCOR) grant on the genomics of heart attack with a $ 17 million award in 2005. His work in genetics has leg honored by the American College of Cardiology with the Simon Dack Award and Lecture in 2005 and at the European Society of Cardiology at the Andreas Gruentzig Award and Lecture in 2004.  in moving to Scripps in 2006, he started the Scripps Genomic Medicine program and recruited a large team to advance Individualized medicine using genomic approaches.  The group formally the Scripps Translational Science Institute,  welke Presently of includes Drs. Steven Steinhubl,  Ali Torkamani, and Nathan Wineinger,  and has multiple NIH funded projects on genomics of cancer, aging, cardiovascular disease, diabetes and pharmacogenomics. It is a major force in San Diego Bringing together basic scientists and clinical investigators from Scripps Health and The Scripps Research Institute Along with researchers from the Salk Institute , Sanford-Burnham Institute , the San Diego Supercomputer Center , and the Children’s Hospital of Philadelphia . Lycra year since 2007 Scripps Genomic Medicine and the Scripps Translational Science Institute put together a major program entitled “Future of Genomic Medicine” welke attracts verschillende hundred clinicians and scientists. In 2009, Sebastopol led the team at Scripps to be the first center to perform routine genotyping or patients under going stenting for variants of the gene CYP2C19 , the major gene implicated in Plavix metabolism.  The first large scale prospective study of consumer genomics, known as the Scripps Genomic Health Initiative was COMPLETED in 2010. Also in 2010, have Initiated the Association for Genomic Medicine dat is dedicated to training physicians in genomics. 
Sebastopol has bone involved with wireless medicine since zijn inception. He was the first physician to serve on CardioNet’s Medical Advisory Board in 1999, the first dedicated wireless medicine company dat performs real-time ECG remote, continuous rhythm monitoring. In 2007 he joined the Board of Sotera Wireless therein has developed the first continuous non-invasive blood pressure monitoring device, welke ook captures all vital signs. In 2008 he forged a new educational program with Qualcomm and Scripps Health to train physicians in wireless medicine, a 2-year Clinician Scholar program: STSI Wireless Health Scholar . At the 2009 International Wireless CTIA meeting, have representation the keynote address on wireless health, the first time this topic has ever leg the subject of a plenary session CTIA: CTIA 2009 Keynote . Also in 2009, he served as Co-Founder with Gary and Mary West to form the West Wireless Health Institute dat is dedicated to advancing healthcare and Reducing costs through innovative wireless solutions. He is the Vice-Chairman of the Institute and its Chief Innovation Officer. He presented at TEDMED the rapid progress being made in this field: TEDMED 2009 Lecture . In addition under in early 2010 Sebastopol showing a wireless medicine presentation at the Consumer Electronics Show , CES 2010 Keynote Highlight . He led the first trial with the GE Vscan device GE Reports , a pocket of high resolution, mobile ultrasound imaging device, introduced in the US in 2010. “The Doctor Will” e “You Now” and is Currently leading clinical trials or heart rhythm and heart failure monitoring wireless devices.
Sebastopol gained Prominence as the first physician researcher to raise questions about the safety of rofecoxib (Vioxx).  Topol was highly critical of Merck ‘s handling of safety issues related to Vioxx. In a 2004 New York Times editorial, he wrote that ‘Merck finally had to acknowledge the truth [about the drug’s cardiovascular risks], but only by accident. ”  Sebastopol ook authored an editorial in the New England Journal of Medicine , arguing that ‘Neither Merck nor the FDA fulfilled zijn responsibilities to the public “and encouraging a” full Congressional review “of the situation. 
In 2004, Bethany McLean , writing in Fortune , questioned Sebastopol’s own potential financial conflicts of interest. She Reported therein Sebastopol served as a scientific adviser to a hedge fund welke profited Substantially in short selling Merck stock, welke plummeted due to the concerns about Vioxx welke Sebastopol had publicized.  Sebastopol denied giving Recruiters the hedge fund advance information, and subsequently severed his ties to industry, Donating all zoals income directly to charity.  In a 2005 JAMA commentary, Topol pointed to synthesis allegations as an example of the complications therein physicians kan experience-when associating with the investment industry, at the time co reiterating that ‘no true conflict of interest existed in this case. ” 
In November 2005, Sebastopol was subpoenaed in a class action Lawsuit Against Merck. He testified dat Vioxx posed an “extraordinary risk”, and therein Raymond Gilmartin , former chief executive officer of Merck, had contacted the head of the Cleveland Clinic board to complain about Topol’s work on Vioxx.  Two days afterward, Sebastopol was informed dat de position as chief academic officer at the Cleveland Clinic had leg abolished, and he was removed as provost of the Cleveland Clinic Lerner College of Medicine, have welke was founded. The Clinic DESCRIBED de timing as coincidental.  The New York Times DESCRIBED Sebastopol’s demotion as part of an “unusually public dispute” tussen Sebastopol and the Cleveland Clinic’s chief executive, Delos Cosgrove , and stated therein Topol’s criticism of Merck had focused scrutiny and criticism on the Clinic’s deep and long standing ties to the pharmaceutical and medical-device industries. 
Sebastopol was selected as one of the 12 “Rock Stars of Science” by GQ and the Geoffrey Beene Foundation in 2009.  He was elected to the American Society for Clinical Investigation , the Association of American Physicians , and the Johns Hopkins Society of Scholars. In 2004, he was elected to the Institute of Medicine of the National Academy of Sciences .  He was named Doctor of the Decade by the Institute for Scientific Information for being one of the top 10 must Cited medical researchers. In 2011, Sebastopol RECEIVED the Hutchinson Medal from the University of Rochester in addition under to giving Recruiters the COMMENCEMENT speech for the School of Medicine and Dentistry. In 2012, Modern Healthcare ranked Sebastopol as the Most Influential physician executive in the United States. 
- Topol, Eric. The Patient Will See You Now: The Future of Medicine is in Your Hands . New York: Basic Books, 2015 – ISBN 9780465054749 
- Topol, Eric. The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care . New York: Basic Books, 2012 – ISBN 9780465025503
- Topol, Eric J., and Paul S. Teirstein. Textbook of Interventional Cardiology . Philadelphia, PA: Elsevier, 2015 – ISBN 9780323340380
- Jump up^ Scripps Translational Science Institute
- Jump up^ The GUSTO investigators (1993). “An international randomized trial Comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators.” New England Journal of Medicine . 329 (10): 673-82. doi : 10.1056 / NEJM199309023291001 . PMID 8204123 .
- Jump up^ Topol EJ, McCarthy J, Gabriel S, et al. (2001). “Single nucleotide polymorphisms in multiple novel thrombospondin genes’ may be associated with familial premature myocardial infarction.” Circulation . 104 (22): 2641-4. doi : 10.1161 / hc4701.100910 . PMID 11723011 .
- Jump up^ Wang L, Fan C, Sebastopol SE, Topol EJ, Wang Q (2003). “Mutation or MEF2A in an Inherited Disorder with Features of Coronary Artery Disease” . Science . 302 (5650): 1578-81. doi : 10.1126 / science.1088477 . PMC 1618876 . PMID 14645853 .
- Jump up^ “About Us | Scripps Translational Science Institute” . Stsiweb.org. Archived from the original on April 12, 2010 . Retrieved 2010-05-05 .
- Jump up^ “Cleveland Clinic Boasts the Nation’s Top Heart Center for the 15th Straight Year” . Cleveland Leader . 2009. Archived from the original on 2010-02-13.
- ^ Jump up to:a b http://www.scripps.org/news_items/2854-noted-cardiologist-eric-j-topol-comes-to-scripps
- Jump up^ Collen D, Topol EJ, Tiefenbrunn AJ, et al. (1984). “Coronary thrombolysis with recombinant human tissue plasminogen activator type: a prospective, randomized, placebo-controlled trial.” Circulation . 70 (6): 1012-1017. doi :10.1161 / 01.CIR.70.6.1012 . PMID 6388898 .
- Jump up^ Topol EJ, McCarthy J, et al. (2001). “Single nucleotide polymorphisms in multiple novel thrombospondin genes’ may be associated with familial premature myocardial infarction.” Circulation . 104 (22): 2641-2644. doi : 10.1161 / hc4701.100910 . PMID 11723011 .
- Jump up^ http://www.stsiweb.org/images/uploads/EJTBibliography-May2010.doc
- Jump up^ http://www.stsiweb.org/index.php/
- Jump up^ http://www.stsiweb.org//about/bio/steinhubl
- Jump up^ http://www.stsiweb.org/index.php/about/bio/torkamani
- Jump up^ http://www.stsiweb.org/index.php/about/bio/wineinger
- Jump up^ http://www.signonsandiego.com/news/2009/oct/30/heart-patients-who-show-mutation-are-unlikely-bene/
- Jump up^ http://www.genomeweb.com/dxpgx/qa-eric-topol-discusses-genomic-medicine-academy-and-getting-docs-excited-about-
- Jump up^ Mukherjee D, Nissen SE, Topol EJ (2001). “Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors”. JAMA . 286 (8): 954-959. doi : 10.1001 / jama.286.8.954 . PMID 11509060 .
- Jump up^ Topol, Eric (October 2, 2004). “Good Riddance to a Bad Drug” . New York Times . Retrieved July 9, 2010 .
- Jump up^ Topol EJ (October 2004). “Failing the public health-rofecoxib, Merck, and the FDA” . N. Engl. J. Med . 351 (17): 1707-9. doi : 10.1056 / NEJMp048286 . PMID 15470193 .
- Jump up^ McLean, Bethany (January 13, 2004). “A Bitter Pill for One Merck Critic” . Fortune . Retrieved July 16, 2010 .
- ^ Jump up to:a b Abelson, Reed; Stephanie Saul (January 17, 2005). “Ties to Industry Cloud a Clinic’s Mission” . New York Times . Retrieved July 16, 2010 .
- Jump up^ Topol EJ, Blumenthal D (June 2005). “Physicians and the investment industry” . JAMA . 293 (21): 2654-7. doi :10.1001 / jama.293.21.2654 . PMID 15928288 .
- Jump up^ Feeley, Jef; Laurel Brubaker Calkins (December 3, 2005). “Merck’s Vioxx Posed` Extraordinary ‘Risk, Cardiologist Contends ” . Bloomberg . Retrieved July 24, 2010 .
- Jump up^ Specter, Michael (2009). Denialism: How Irrational Thinking Hinders Scientific Progress, Harms the Planet, and threatens Our Lives . Penguin Books . ISBN 978-1-59420-230-8 .
- Jump up^ “RSOS Eric Topol, MD” . Rock Stars of Science . Retrieved 2010-05-12 .
- Jump up^ “Eric Topol elected to IOM NAS” . Retrieved 2010-05-26 .
- Jump up^ “San Diego’s Sebastopol named nation’s top physician executive” . Retrieved 2012-04-23 .
- Jump up^ Chitty, Mary (January 14, 2015). “The Future volgens to Sebastopol” . Clinical Informatics News . Needham, Massachusetts, United States: Cambridge Health Tech Institute.